Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3997475 | 0.89 | RAB9A (0.45) | MMP12KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL30799511 | 0.89 | RAB9A (0.45) | MMP12KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL2017082 | 0.87 | MMP12 (0.63) | MMP12PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL30138402 | 0.86 | HTR1D (0.47) | MMP12HTR1DCA2RAB9ANPC1 | |
| SCHEMBL4606421 | 0.84 | MMP12 (0.47) | MMP12KDM4EALDH1A1RAB9ANPC1 | |
| SCHEMBL6364795 | 0.84 | KMT2A (0.46) | MMP12KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL30138396 | 0.83 | HTR1A (0.48) | MMP12HTR1DKDM4EALDH1A1PDGFRB | |
| SCHEMBL29687354 | 0.83 | ELANE (0.47) | MMP12HTR1DCA2RAB9ANPC1 | |
| SCHEMBL30799913 | 0.82 | CA2 (0.46) | MMP12CA2KDM4EALDH1A1HPGD | |
| SCHEMBL29687408 | 0.81 | MMP12 (0.41) | MMP12KDM4EALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | YODA THERAPEUTICS INC. (TW) | 2023-01-19 | — | — | US | disclosed |
| US-11370775-B2 | Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors | Tseng, Yufeng Jane (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | NLRP3, NOD1, NLRP1 | MMP12 874/4885PDE3B 2377/4885PDE3A 2225/4885 |
| US-11370775-B2 | Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors | DAO, DDO, IL4I1 | MMP12 1722/4885PDE3B 785/4885PDE3A 782/4885 |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | OPRK1, OPRL1, OPRD1 | MMP12 2506/4885PDE3B 604/4885PDE3A 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.